CORD has partnered with the Economic Club of Canada (ECC) to present Canada’s Rare Disease Strategy in Toronto on September 24, 2015 and other cities are planned across Canada.
Location and Date:
Rare Diseases: A Public Health Issue
In just a few years, Canada has emerged from a state of “not needing an Orphan Drug Policy” to becoming an acknowledged global leader in rare diseases, especially in research and patient advocacy. Which makes now a very good time to focus our efforts toward implementing Canada’s Rare Disease Strategy.
Admittedly, Canada has been late to embrace rare diseases. It was just five years ago that CORD pointed out that Canadians had access to only half of the orphan drugs approved in the USA and/or Europe. Approved drugs were routinely rejected for coverage by the public drug plans. Even today, there remains a lag of two to seven years for patients to get access. Similarly, over the past 30 years, while the USA, Europe, and Japan have invested hundreds of millions of dollars in rare disease research, Canada did not target research funding for rare diseases until 2012. But things are changing rapidly, with Canada’s Orphan Drug Regulatory Framework due to be implemented imminently and Canadian research sites now among the leaders in international collaborative projects.
Similarly, in 2009 when the European Union called for the development of national rare disease plans, almost all member states responded, as have countries outside the EU, such as Mexico and Peru. Integral to the national plans are Centres of Reference, for which the EU will issue a call for proposals in fall 2015.
Meanwhile in Canada, we have pockets of rare disease expertise, but most are neither linked to general practitioners and paediatricians nor formally to one another. Hence the need for the coalescing force of Canada’s Rare Disease Strategy and the call to collaborate on a five-point action plan so that collectively we can:
A key to success in Europe has been endorsement of “solidarity” as a fundamental value and “equal access” as a guiding principle for all patients regardless of what they suffer from or where they live. Rare diseases are not limited to a small population but are regarded as a public health issue affecting everyone.
Intended Audience: Senior Leaders from business, government industry, academic and media organizations.
Media Coverage: The dialogues are intended to be a high profile event with extensive media coverage. CPAC will be invited, as will leading health reporters and advocacy groups from across the country.
Moderated by: The Honourable Fred Horne, Former Minister of Health, Alberta
June 14, 2017
Delta Hotel Toronto, 75 Lower Simcoe Street
Roadmap to Optimal Drug Access Amendments to Patented Medicines Regulations and Ontario Kids’ Pharmacare (OHIP+)DRAFT AGENDA WHAT WE WANT TO ACHIEVE Outcome: Each stakeholder to be able to provide meaningful input on Amendments to Patented Medicines Regulations benefitting from perspectives of others To that end Share expertise, knowledge, and evidence Exchange needs, interests, and concerns Deliberate toward common positions Recognize unique views In the end Expand mandate from simplistic singular focus of “protecting Canadians from excessive drug prices” to realistic collective goal of “ensuring all Canadians have access to best possible medicines at prices that are affordable today and invest in tomorrow.” * To receive member rates you must login at the top right hand corner of raredisorders.ca Refund Policy: Cancellations received a minimum of 15 days prior to the event will receive a refund minus an administrative fee of $15.00. This fee covers the cost of processing the registration and refund. Cancellations received after the 15-day deadline and no-shows are non-refundable.